Advanced Filters
noise

leukemia Clinical Trials

A listing of leukemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 1,150 clinical trials
H Hyery KIM, MD, PhD

Treatment of Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia in Children

Aim of this study is to investigate the outcome of NGS MRD based risk stratified treatment for high risk acute lymphoblastic leukemia in children and adolescents.

1 - 9 years of age All Phase 2
R Robert J. Kreitman

Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia

This phase II trial tests how well venetoclax works in treating patients with hairy cell leukemia that has come back after a period of improvement (relapsed). Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a …

18 years of age All Phase 2
J Jin Jie

Clinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia

The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of WBC100 capsules in patients with relapsed or refractory acute myeloid leukemia (R/R AML). The main questions it aims to answer are: What is the safety and tolerability profile of WBC100 in R/R …

18 years of age All Phase 1
z zhimin Zhai, Ph.D

EX02 CAR-T Cells for Relapsed and Refractory Acute Myeloid Leukemia

This is a early Phase 1 open-label, single-arm clinical study of EX02 CAR-T therapy for relapsed and refractory acute myeloid leukemia. Each participant will undergo leukapheresis after enrolment, receive treatment of the conditioning chemotherapy of cyclophosphamide and fludarabine, and an an intravenous infusion of CAR-T cells. Each participant will proceed …

18 - 70 years of age All Phase N/A
F Feifei Tang

Interferon-alpha As Maintenance Therapy for Favorable-risk Acute Myeloid Leukemia

This research focuses on a prospective, randomized, controlled trial of "Interferon-alpha as maintenance therapy for favorable-risk acute myeloid leukemia." By fully utilizing prospective, randomized, controlled clinical trial and studying the negative conversion of MRD and the survival of favorable-risk AML patients, it aims to explore the efficacy and safety of …

18 - 70 years of age All Phase 3
S Suning Chen

a New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid Leukemia

This is a single arm, open-label, multicenter clinical trial to evaluate the efficacy and safety of ivosidenib+venetoclax+ azacitidine in adult Chinese subjects with newly diagnosed IDH1m AML.A total of approximately 42 China Nationwide subjects with newly diagnosed IDH1m AML will participate in the study.The primary endpoint of the study is …

18 years of age All Phase 2
B Brett Houston, MD

Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia

Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are serious, life changing blood cancers. Patients with MDS and AML commonly experience complications related to bleeding, which affect patient quality-of-life and can sometimes lead to hospitalization or death. The investigators will conduct a randomized controlled trial to evaluate the effectiveness and …

18 years of age All Phase 2
Q Qian Jiang, MD

TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients

A Phase II study evaluating the safety and efficacy of TGRX-678 in Chronic Myelogenous Leukemia (CML) patients in Accelerated phase (AP) and are relapsed or refractory from third-generation Tyrosine Kinase Inhibitor (TKI) treatment

18 years of age All Phase 2
M Madeline Krause, MSEd

Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care

The purpose of this study is to learn about the impact that the services and programs provided by the Leukemia and Lymphoma Society have among patients with blood cancer, such as access to care, quality of life, and financial burden.

18 years of age All Phase N/A
A Amanda Blackmon

MiRisten for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

This phase I trial tests the safety, side effects, and best dose of miRisten in treating patients with acute myeloid leukemia (AML) that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). MiRisten may stop the growth of cancer cells by …

18 years of age All Phase 1

Simplify language using AI